MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
uniQure N.V. Net Income 2011-2026 | QURE
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income uniQure N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -240 M | -308 M | -127 M | 330 M | -125 M | -124 M | -83.3 M | -79.3 M | -73.4 M | -78.1 M | -45 M | -37 M | -19.5 M | -22.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 330 M | -308 M | -73.8 M |
Quarterly Net Income uniQure N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -80.5 M | -37.7 M | -43.6 M | - | -44.4 M | -56.3 M | -65.6 M | - | -89.6 M | -68.5 M | -77.2 M | - | -47.9 M | -39.1 M | -46.7 M | - | 321 M | 358 M | -41.6 M | - | -124 M | -70.6 M | -28 M | - | -82.8 M | -59.2 M | -27.8 M | - | -61.4 M | -39.4 M | -18.8 M | - | -51.8 M | -41.5 M | -20.3 M | - | -15.3 M | -21.1 M | -22.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 358 M | -124 M | -24.8 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
Adagene
ADAG
|
-33.4 M | $ 1.9 | -3.11 % | $ 107 M |  China |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K |  USA |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
160 M | $ 25.88 | -0.73 % | $ 1.25 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.31 | -4.06 % | $ 7.96 B |  Australia |
 |
Aptose Biosciences
APTO
|
-25.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.7 | 1.5 % | $ 17 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-208 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Brickell Biotech
BBI
|
-5.69 M | - | -5.38 % | $ 6.06 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-27.1 M | $ 2.9 | 0.52 % | $ 908 M |  Israel |
 |
BeiGene, Ltd.
BGNE
|
-645 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioNTech SE
BNTX
|
10.3 B | $ 106.07 | -2.69 % | $ 27.2 B | Germany |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.88 M | $ 3.96 | -1.0 % | $ 8.62 B | Israel |
 |
CASI Pharmaceuticals
CASI
|
-36.7 M | $ 0.95 | -0.72 % | $ 129 M | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 215.17 | 4.54 % | $ 5 B |  Danmark |
 |
Bellicum Pharmaceuticals
BLCM
|
-25 M | - | -9.72 % | $ 5.89 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Bio-Path Holdings
BPTH
|
-16.1 M | - | - | $ 100 K | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Baudax Bio
BXRX
|
-58.8 M | - | 0.59 % | $ 63 K | USA |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 25.17 | -1.89 % | $ 1.62 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 64.51 | 1.04 % | $ 8.63 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
164 M | $ 23.24 | 2.38 % | $ 2.75 B | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 9.65 | -0.72 % | $ 1.56 B | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
-114 M | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 14.0 | 3.63 % | $ 922 M | USA |
 |
Biogen
BIIB
|
1.63 B | $ 164.49 | 0.04 % | $ 23.9 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Avid Bioservices
CDMO
|
-141 M | - | - | $ 789 M | USA |
 |
BioVie
BIVI
|
-17.5 M | $ 1.24 | 2.49 % | $ 1.83 M | USA |
 |
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | USA |